BioSpace News Archive

Willow Biosciences Inc announces execution of a commercial agreement with Sandhill One, LLC.

Lucid Diagnostics Inc. announced that Noridian Healthcare Solutions, the Medicare Administrative Contractor whose geographic Jurisdiction E covers Lucid’s CLIA laboratory in Lake Forest, CA, has published a Future Effective Local Coverage Determination DL39262, on molecular testing for esophageal precancer and cancer in Medicare beneficiaries, to become effective May 28, 2023.

MAIA Biotechnology, Inc. (NYSE American: MAIA) today announced the peer-reviewed publication of original research article in this month’s issue of Molecular Cancer Therapeutics (volume 22, issue 4), a renowned American Association of Cancer Research (AACR) journal that publishes translational research studies focused on the discovery and preclinical development of therapeutic agents for oncology.

ImCheck Therapeutics announced today data from its ongoing Phase I/IIa clinical trial EVICTION-2 at the American Association for Cancer Research (AACR) Annual Meeting 2023 in a poster presentation (CT179) titled: “First-in-Human Study of ICT01, an Anti-BTN3A Activating Monoclonal Antibody in Combination with Low Dose IL-2 in Patients with Advanced Solid Tumors (EVICTION-2 Study)”.

EvolveImmune Therapeutics, an immuno-oncology company developing first-in-category, multifunctional biotherapeutics to overcome cancer-driven immunodeficiency, today announced the presentation of the first data highlighting the company’s proprietary CRISPR-Cas9 T cell exhaustion screening platform.

Notable Labs, Inc. (“Notable”) today announced clinical data regarding its Predictive Precision Medicine Platform (PPMP) at the 2023 American Association for Cancer Research (AACR) Annual Meeting being held in Orlando, Florida from April 14-19, 2023.

Technoderma Medicines, Inc. (“the Company”), a clinical stage biopharmaceutical company, is pleased to report that the Company has begun dosing patients in its Androgenetic Alopecia (AGA) Phase 2 clinical trial (NCT05802173) of topical TDM-105795 solution.

Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the presentation of new preclinical data supporting the intracranial activity NVL-655.

KT®, the number one kinesiology tape brand, today launched KT Tape PRO Oxygen – the first kinesiology tape to feature CELLIANT® Infrared Technology from Hologenix.

FirstHealth of the Carolinas, Inc. and GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, today announced the availability of GalleriⓇ, a multi-cancer early detection (MCED) screening test to eligible patients initially through FirstHealth’s Concierge Medicine Clinic in Southern Pines.